Per-protocol analysis of the ZINC trial for HIV disease among alcohol users

Sara Lodi, Matthew Freiberg, Natalia Gnatienko, Elena Blokhina, Tatiana Yaroslavtseva, Evgeny Krupitsky, Eleanor Murray, Jeffrey H Samet, Debbie M Cheng, Sara Lodi, Matthew Freiberg, Natalia Gnatienko, Elena Blokhina, Tatiana Yaroslavtseva, Evgeny Krupitsky, Eleanor Murray, Jeffrey H Samet, Debbie M Cheng

Abstract

Background: The Zinc for INflammation and Chronic disease in HIV (ZINC) trial randomized person who live with HIV (PLWH) who engage in heavy drinking to either daily zinc supplementation or placebo. The primary outcome was change in the Veterans Aging Cohort Study (VACS) index, a predictor of mortality, between baseline and 18 months. Because adherence and follow-up were suboptimal, the intention-to-treat analysis, which was not statistically significant, may have underestimated the effect of the zinc supplementation.

Objective: We estimated the per-protocol effect of zinc versus placebo in the ZINC trial (i.e., the effect that would have been observed if all participants had had high adherence and none was lost to follow-up).

Methods: Adherence was measured as the self-reported percentage of pills taken in the previous 6 weeks and assessed at all post-baseline visits. We used inverse probability weighting to estimate and compare the change in the VACS index at 18 months in the zinc and placebo groups, had all the trial participants had high adherence (i.e., cumulative adherence ≥80% at 18 months). To examine trends by level of adherence, we rerun the analyses using thresholds for high adherence of 70% and 90% of average self-reported pill coverage.

Results: The estimated (95% confidence interval) change in the VACS index was - 2.16 (- 8.07, 3.59) and 5.84 (0.73, 11.80) under high adherence and no loss to follow-up in the zinc and placebo groups, respectively. The per-protocol effect estimate of the mean difference in the change between the zinc and placebo groups was - 8.01 (- 16.42, 0.01), somewhat larger than the intention-to-treat effect difference in change (- 4.68 (- 9.62, 0.25)), but it was still not statistically significant. The mean difference in the change between individuals in the zinc and placebo groups was - 4.07 (- 11.5, 2.75) and -12.34 (- 20.14, -4.14) for high adherence defined as 70% and 90% of pill coverage, respectively.

Conclusions: Overall, high adherence to zinc was associated with a lower VACS score, but confidence intervals were wide and crossed 0. Further studies with a larger sample size are needed to quantify the benefits of zinc supplementation in this population.

Trial registration: ClinicalTrials.gov NCT01934803 . Registered on August 30, 2013.

Keywords: Alcohol abuse; HIV; Inverse probability weighting; Per-protocol; Zinc.

Conflict of interest statement

Debbie Cheng serves on Data Safety Monitoring Boards for Janssen Research & Development. The other authors declare that they have no competing interests.

References

    1. Bao B, Prasad AS, Beck FW, Fitzgerald JT, Snell D, Bao GW, et al. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr. 2010;91(6):1634–1641. doi: 10.3945/ajcn.2009.28836.
    1. Baum MK, Lai S, Sales S, Page JB, Campa A. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin Infect Dis. 2010;50(12):1653–1660. doi: 10.1086/652864.
    1. Gnatienko N, Freiberg MS, Blokhina E, Yaroslavtseva T, Bridden C, Cheng DM, Chaisson CE, Lioznov D, Bendiks S, Koerbel G, Coleman SM, Krupitsky E, Samet JH. Design of a randomized controlled trial of zinc supplementation to improve markers of mortality and HIV disease progression in HIV-positive drinkers in St. Petersburg, Russia. HIV Clin Trials. 2018;19(3):101–111. doi: 10.1080/15284336.2018.1459344.
    1. Freiberg MS, Cheng DM, Gnatienko N, Blokhina E, Coleman SM, Doyle MF, et al. Effect of zinc supplementation vs placebo on mortality risk and HIV disease progression among HIV-positive adults with heavy alcohol use: a randomized clinical trial. JAMA Netw Open. 2020;3(5):e204330. doi: 10.1001/jamanetworkopen.2020.4330.
    1. Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ, NA-ACCORD and VACS Project Teams Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62(2):149–163. doi: 10.1097/QAI.0b013e31827df36c.
    1. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S. Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, APRICOT Clinical Investigators Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi: 10.1002/hep.21178.
    1. Hernán MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377(14):1391–1398. doi: 10.1056/NEJMsm1605385.
    1. Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1):48–55. doi: 10.1177/1740774511420743.
    1. Murray EJ, Hernan MA. Adherence adjustment in the Coronary Drug Project: a call for better per-protocol effect estimates in randomized trials. Clin Trials. 2016;13(4):372–378. doi: 10.1177/1740774516634335.
    1. Murray EJ, Hernan MA. Improved adherence adjustment in the Coronary Drug Project. Trials. 2018;19(1):158. doi: 10.1186/s13063-018-2519-5.
    1. Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA, INSIGHT START Study Group and the HIV-CAUSAL Collaboration Effect estimates in randomized trials and observational studies: comparing apples with apples. Am J Epidemiol. 2019;188(8):1569–1577. doi: 10.1093/aje/kwz100.
    1. Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA, INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. AIDS. 2016;30(17):2659–2663. doi: 10.1097/QAD.0000000000001243.
    1. Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM, Partners PrEP Study Team Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(13):2155–2160. doi: 10.1097/QAD.0b013e3283629037.
    1. NIAAA . Helping patients who drink too much: a clinician’s guide. Updated 2005 edition. Bethesda, MD: National Institutes of Health; 2005. National Institute on Alcohol Abuse and Alcoholism.
    1. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656–664. doi: 10.1093/aje/kwn164.
    1. Hernán MA, Robins JM. Causal inference: what if? Forthcoming ed. Boca Raton, FL: Chapman & Hall/CRC; 2021.
    1. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–560. doi: 10.1097/00001648-200009000-00011.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit